Tempus AI, an artificial intelligence-driven precision medicine company, has completed its acquisition of Ambry Genetics, a genetic testing company focused on improving health by understanding the relationship between genetics and disease. The deal, valued at USD 600 million, includes USD 375 million in cash and USD 225 million in shares, with USD 100 million subject to a one-year lock-up. Financing was provided by Ares Management Credit Funds.
Also Read: Corti Launches Specialised AI Models for Healthcare
Tempus AI Acquires Ambry Genetics
The…